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Introduction Mass drug administration (MDA) means once-in-a-year administration of 
Diethyl Carbamazine (DEC) tablet to all people (excluding children under 2 
years, pregnant women and severely ill persons) in identified endemic areas. 
It aims at cessation of transmission of Lymphatic Filariasis.  To study the 
coverage and compliance of MDA in Satna district during the campaign in 
June 2013. 
Methods Cross-sectional observational study. Setting: Urban And Rural Areas In Satna 
District Identified As Endemic For Filariasis Where MDA 2013 Was 
Undertaken. Study Variables: Exploratory - Rural and urban clusters of Satna 
district; Outcome - coverage, compliance, actual coverage, side effects. 
Results Four clusters, each comprising 30 households from the Satna endemic 
district, yielded an eligible population of 650 (95.87%) of total 678. The 
coverage was 586 (90.15% out of eligible population) with variation across 
different areas. The compliance with drug ingestion was 88.05% with a gap 
of 11.95% to be targeted by intensive IEC. The effective coverage (79.38%) 
was below the target (85%). Side effects of DEC were minimum, transient 
and drug-specific. 
Conclusions Overall coverage was marginally better in rural areas. The causes of poor 
coverage and compliance have been discussed and relevant suggestions have 
been made. 
Keywords Diethyl Carbamazine - MDA - Lymphatic Filariasis. 
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INTRODUCTION 
Lymphatic Filariasis (LF) is an important public 
health problem next to malaria in India
1
. WHO had 
recently called on member states to identify the 
global elimination of LF as a public health priority 
2
. The International Task Force for Disease 
Eradication too had identified LF as one of the 
seven infectious diseases considered eradicable or 
potentially eradicable
3
. Several interventions have 
been tried in recent times to deal with this health 
problem. Mass drug administration (MDA), which 
means once-in-a-year administration of Diethyl 
Carbamazine (DEC) tablet to all people (excluding 
children under 2 years, pregnant women and 
severely ill persons) in identified endemic areas, is 
one of them
4
.
 
It aims at cessation of transmission of 
LF in the community. MDA in combination with 
other techniques has already eliminated LF from 
Japan, Taiwan, South Korea and Solomon Islands 
and markedly reduced the transmission in China 
5,6
.
 
MDA has been as effective as 12-day therapy, as a 
public health measure, with lesser side effects, thus 
enhancing public compliance and decreasing 
delivery costs
7
. It does not require complex 
management and infrastructure, and can be 
integrated into the existing primary health care 
(PHC) system. In order to achieve the elimination 
of LF by 2015 under the National Health Policy, 
National Filarial Day (NFD) was proposed to be 
observed every year starting from 2004 in the 
endemic districts
8
.
 
 Based on microfilaria surveys 
and the line listing of lymphoedema cases, Madhya 
Pradesh had identified 11 districts and accordingly 
they were included for observing MDA since 2004. 
The present communication deals only with the 
evaluation of coverage (distribution of drug to the 
community) and compliance (actual drug 
consumption) of MDA in June 2013 in endemic 
areas (Satna district) of Madhya Pradesh. 
 
General Objective 
To find out the coverage and compliance of MDA 
in Satna district during the campaign in June 2013. 
 
Specific Objectives: 
Objectives dealt in this communication were: 
1. To review the progress of activities of single 
dose DEC mass administration in the selected 
district. 
2. To assess independently the program 
implementation with respect to process and 
outcome indicators. 
3. To recommend mid-course correction and 
suggest necessary steps for further course of 
action. 
 
METHODS 
MDA was undertaken in identified endemic areas 
in 2013. The activities under MDA involved 
administration of DEC tablets to eligible 
population from endemic area by health staff and 
Integrated Child Development Scheme (ICDS) 
functionaries referred as drug distributors (DD) 
make house-to-house visits on select dates in 2013. 
DEC was administered to all people (excluding 
children under 2 years, pregnant women and 
severely ill persons) with the instruction to ingest 
the tablet preferably on the spot. 
 
Selection of the Survey Area 
Four clusters of district (one from urban and three 
from rural areas) were identified for the survey. 
Thus, a total of 4 clusters were studied. The survey 
was done 2 months after the MDA and the 
coverage reported by the health system was used to 
select the clusters. The selection of various health 
centres for the further selection of four clusters was 
done as per the following criterias of National 
Vector Born Disease Control Programme 
(NVDCP) of Govt. of India: 
1. One PHC with >80% (highest) MDA coverage 
reported by District Health officials. 
2. One PHC with 50-80% (medium)  MDA 
coverage reported by District Health officials  
3. One PHC with up to 50% (lowest)  MDA 
coverage reported by District Health officials  
4. One Urban area irrespective of MDA coverage 
reported by District Health officials. 
 
After the selection of four clusters as per 
NVDCP,GoI Guideline , at least 30 households 
HHs) were selected from each clusters hence total 
120 HHs (90 HHs from Rural & 30 HHs from 
Urban) were enrolled in the present study.Hence 
total population of 678 (548 out of 90HHs - rural 
and 130 out of 30 HHs- urban) was analysed in the 
present study. 
A total of 30 households (HHs) in each 
cluster was selected in such a way that the entire 
ward/village was represented. For this purpose, the 
area was divided into four quadrants, and in each 
quadrant, a central point was identified and the first 
house was selected randomly (any number between 
1 and 9) and thereafter another seven HHs (total 
eight) serially (open with available family 
members) were covered. The exercise was repeated 
in the other three quadrants. In fact, this was an 
improvement over 30 HHs suggested per cluster by 
NVBDCP for evaluation
4
. The collection of 30 HH 
sample from different areas has been taken as per 
NVBDCP guidelines because the validity of 
sampling was found most appropriate when it is 30 
in number selection. 
All the data were collected in a predesigned 
and structured proforma. After data collection, 
analysis was done with the help of Epi Info. 
 
Place of Study 
Four clusters (Named Jamuna SHC Jamuna PHC 
Rampur baghalan,; Saraiya tola SHC Saraiya tola 
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PHC Kothi,; Akaha SHC Akaha PHC Uchehara,; 
Satna urban Nai basti ward no. 17 District hospital 
Satna). 
 
OBSERVATIONS AND DISCUSSION 
A total of 4 clusters including 1 from urban and 3 
from rural areas were studied. Together, these 4 
clusters covered a total of 120 HHs (90 rural and 
30 urban) and yielded a population of 678 (548 - 
rural and 130- urban). In the studied clusters, 
against a population of 678, 650 (95.87%) were 
eligible for MDA [Table 1].  
 
 
Table 1 Distribution of population of surveyed districts 
 
SATNA TOTAL 
POPULATION 
ELIGIBLE 
POPULATION 
POPULATION 
COVERED ( OUT OF 
ELIGIBLE) 
N % N % 
JAMUNA 187 180 96.25 163 90.55 
SARIYA TOLA 171 164 95.90 148 90.24 
AKAHA 190 181 95.26 179 98.89 
WARD NO. 17 130 125 96.15 96 76.80 
TOTAL 678 650 95.87 586 90.15 
 
Adhering to the criteria of NVBDCP, the 
eligible population in various clusters varied 
between 95.2% and 96.2%. The proportions of 
eligible population in rural and urban clusters were 
93.3 and 76.8%, respectively. The rest was either 
below 2 years of age (n=21), pregnant females 
(n=03) or severely ill (n=04.) Out of 650 persons 
eligible, 586 (90.15 %) received DEC [Table 1]. 
Against overall coverage rate of 90.15 %, it was 
highest in Akaha (98.89 %) and lowest in Ward no. 
17 Nai Basti (76.80%). The remaining (n = 64) 
although eligible did not get the drug for various 
reasons. The common reasons were DD did not 
visit (n=50), followed by houses were locked or 
people were not available (n=14). All these 
problems require powerful advocacy tools and 
strategies
9
. The 79.38% coverage observed by us 
was not satisfactory because under the MDA, the 
target was to ensure effective coverage of 85% - a 
product of coverage as well as compliance. The 
main reasons for no coverage were that workers 
could not cover the population or did not 
administer drug and importantly the 
misclassification of persons rendering them not 
eligible. It can be improved by making efficient 
micro-plans, improved supervision and 
emphasizing more strongly the selection criteria in 
training. 
 
Table 2 Compliance rate, coverage-compliance gap and effective coverage rate 
 
DISTRICT  
SATNA  
ELIGIBLE 
POPULATIO
N 
DEC 
GIVEN 
BY DD 
CONSUMED ( 
COMPLIANCE 
RATE) 
COVERAGE – 
COMPLIANCE 
GAP 
EFFECTIVE 
COVERAGE 
RATE 
N % % % 
JAMUNA 180 163 160 98.15 1.85 88.88 
SARIYA TOLA 164 148 107 72.29 27.70 65.24 
AKAHA 181 179 170 94.97 5.03 93.92 
WARD NO. 17 125 96 79 82.29 17.71 63.20 
TOTAL 650 586 516 88.05 11.95 79.38 
 
Compliance rate (ingestion of drug by 
those who received it) was 88.05 % with lowest in 
Sariya tola (72.29 %) and highest in Jamuna (98.15 
%).  A total of 70 persons accounted for this gap. 
The main reason for this was fear of side effects 
(n= 46) and the rest (n=24) either forgot to take or 
misplaced the drug. Effective coverage rate is the 
end product of coverage by the health system and 
compliance by community. It was 79.38% less than 
the target (85%) for the entire District as a whole. It 
was highest in Akaha (93.92%) and lowest in Ward 
no. 17 nai basti (63.2%) (Table 2). In fact, the 
district could NOT achieve the targeted coverage of 
85%. Effective coverage rate is the end product of 
coverage of the health system and compliance by 
community. In fact this should be 85% or above for 
the elimination of disease. Overall, it was 79.38% 
for the district. Good coverage in the absence of 
good compliance and similarly motivated 
community (for good compliance) with poor 
coverage will be of little use. The coverage in the 
districts of 79.38% was below the target of 85%.   
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Table 3 Drug coverage and compliance rates in urban and rural settings 
 
Satna Coverage rate 
Out of eligible (%) 
Compliance rate (%) CCG (%) Effective coverage rate 
(%) 
Urban (n=130) 76.80 82.29 17.71 63.20 
Rural  (n=548) 93.33 89.18 10.82 83.23 
Total  (n=678) 90.15 88.05 11.95 79.38 
 
Both coverage and compliance were 
marginally better in rural areas (93.33 %, 89.18 % 
respectively) as compared to urban areas (76.80 %, 
& 82.29 % respectively), and accordingly the 
actual coverage too was better in rural areas [Table 
3]. CCG helps to understand why people fail to 
consume the drug. It was around 11.95% and needs 
to be bridged with side by side efforts through IEC 
from all possible channels to motivate people for 
ingestion (preferably on the spot) of the drug. It 
seems that LF is not perceived as a serious public 
health problem or people think that they will not be 
affected by this disease. All these point out to one 
thing that there is no resistance in the community 
for DEC; however, more important is to emphasize 
on supervised “on the spot” DEC consumption. 
One reason commonly given by the 
community for not consuming DEC on the spot 
was that it causes gastric upsets and so they prefer 
to take it after the meal. In this regard, a suggestion 
came to us that DD may carry small packets of 
biscuits (costing about USD 0.03.) to facilitate spot 
consumption of DEC. As such, the side effects 
were very few and they were also minor, transient 
and drug-specific. However, they also need to be 
addressed as they constitute the cause of 
noncompliance. Information about the Rapid 
Response Team (RRT) must be widely publicized 
in order to increase the faith of people and will 
indirectly result in better compliance. 
Coverage and Compliance of Mass Drug 
Administration for Elimination of Lymphatic 
Filariasis in Endemic Areas of Bijapur district, 
Karnataka by Dr. Ravish K.S. et al. also observed 
that the survey coverage rate was 85.9% in the 
study population in 2012. The difference of 14% 
could be attributed to people not having received 
tablets either because they were not at home when 
distributors visited or distributors having not 
visited their houses at all. Distributors have not 
visited few houses because of confusion in area 
demarcation. In the study compliance rate was 
45.9%. There was hardly any stress on supervised 
“on the spot” consumption of tablets. Compliance 
rate was bit better where health staff was deputed 
for drug distribution
10
.
 
 Kumar et al. the coverage 
was 85.2% and compliance was 60% and in B.V. 
Babu Study in Orissa it was seen that coverage was 
67% and compliance was 42% 
11,12
.
 
 
Among the 989 people who did not 
consume tablets – 512 i.e., 51.8% people said that 
they have not been informed properly about why 
and how much they should consume. Fifteen 
percent of people did not consume tablets for the 
fear of the reaction. Seven percent of the people did 
not consume tablets because either they feel they 
are healthy or sick. So almost 74% people did not 
consume because of inadequate information from 
drug distributors. 15.7% of people were not at 
home during the activity. 10.3% people have not 
received tablets though they were at home. 
Adverse reactions among the study 
population were only 0.6%, which is negligible. 
The following adverse reactions noted were 
giddiness, vomiting, gastric irritation, etc., which 
were mild. Even though adverse reactions were 
negligible, people should be made aware of it 
through IEC, because only sustained high 
compliance can lead to elimination of Filariasis. 
MDA coverage evaluation survey for LF 
in Bagalkot and Gulbarga districts by Prakash 
Kurubarahalli Patel in their study found that 
Approximately 79% in Bagalkot and 39% of the 
study subjects in Gulbarga district reported that 
they actually consumed both DEC and albendazole 
tablets. The remaining were, either who did not 
consume at all or consumed inadequate dosage of 
the tablets, the prime reasons for not consuming the 
tablet was, not received tablet (27.9%), followed by 
not present at home (18.4%) and drug given at 
home but no information (9.5%) in Bagalkot 
district. However, the main reason in Gulbarga 
district was fear of side effects (51.2%) and did not 
receive tablets (15.2%). Only 8% of people who 
consumed tablets in Bagalkot district and 2.3% in 
Gulbarga district actually experienced side 
effects
13
. 
 
CONCLUSIONS AND 
RECOMMENDATIONS 
Coverage and compliance were marginally better in 
rural areas. Coverage-compliance gap was around 
11.95% as whole (17.71% in urban and 10.82 % in 
rural area. There was hardly any resistance in the 
community for the program and no one refused to 
accept drug. Similarly, refusal to taking drug for 
fear of side effects accounted for about (n = 46) of 
noncompliance. Efforts are needed to reduce this 
gap before increasing the coverage. It needs 
motivating and sensitizing the community through 
IEC. Incidence of side effects after MDA was 
minimal. All side effects were mild and needed no 
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medical intervention; however, the community was 
largely unaware of RRT. 
DD hardly insisted on supervised “on the 
spot” administration of drugs; therefore, supervised 
drug intake was nil or poor and the commonest 
answer was “will take after meal”. Efforts should 
be made to insist on “on the spot” consumption. 
This alone can bring down the coverage-
compliance gap considerably. Inclusion criteria 
were misunderstood. In some clusters DD, by 
mistake of their own,   DEC was not given to 
persons who were having diabetes or hypertension. 
In our evaluation, we considered such persons 
eligible. Therefore, the coverage and effective 
coverage decreased in our evaluation. Training of 
DD in future should focus on the point that 
anybody who is above 2 years of age, non-pregnant 
and not critically ill (having some acute illness or 
hospitalization) must receive the drug. 
DEC tab should be dispensed in 100 mg, 
200 mg and 300 mg single doses that may be color 
coded for effectively implement in field as per 
requirement, because there is a misbelieve and fear 
in person to taking more than one tab on single 
time and they prefer to take after it at regular 
interval of about 8 hours. Various modes of pre-
MDA IEC can be utilized such as radio, TV, cable, 
newspapers, recorded messages or SMS (mobile or 
landline phones) and should be done just few days 
before the campaign. IEC should focus on the 
following:  
 
a. Threat perception of Filariasis was very poor 
among people as it is not a visible disease, but 
still it is a threat as many people are at risk, and 
taking DEC only once in a year can prevent it. 
b. The single-dose DEC once in a year is an 
effective preventive tool while in treatment a 
person may have to take it for 21 days. Even 
many practicing doctors are also not clear about 
it. 
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